Price
$5.65-28.30%Social Signal Score
Analyst Ratings
10 analysts52-week range
- Last close
- $5.65
- Off 52w high
- -62.0%
- 200-day average
- $8.78
- vs 200-day
- -35.6%
Revenue
$33.66MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Donn Casale
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 195
- Beta
- 0.88
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -2.91
Financials
Revenue
$33.66M+1493.7%Net Income
$-62.34MEBITDA
$-59.44MFree Cash Flow
$-60.93MEPS (diluted)
$-0.63Shares Outstanding (diluted)
99.31M+200.3%Operating Expenses
$82.28MCash & Debt
$143.84MRevenue by Segment (annual)
$72.19MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $84.28M | $-171.30M | $-1.74 |
| 2024 | $89.15M | $8.00M | $0.08 |
| 2023 | $30.0K | $-54.37M | $-0.57 |
| 2022 | $1.32M | $-34.68M | $-0.87 |
| 2021 | $5.51M | $-20.24M | $-0.70 |
| 2020 | $17.84M | $-1.06M | $-0.03 |
| 2019 | $0.00 | $-23.97M | $-0.72 |
| 2018 | $0.00 | $-17.58M | $-0.53 |
Valuation
SPRYhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50Social Signal Score
Mentions (13)
- Newsglobenewswire.com·7d ago·Neutral
Portnoy Law Firm Announces Class Action on Behalf of ARS Pharmaceuticals, Inc. Investors LOS ANGELES, Sept. 29, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises ARS Pharmaceuticals, Inc., (“ARS” or the "Company") (NASDAQ: SPRY) investors of a class action on behalf of investors that bought securities between March 9, 2026 and June 24, 2026, inclusive (the “Class Period”).
View source ↗ - Newsgurufocus.com·29d ago·Negative
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit PR Newswire NEW YORK, S
View source ↗ - Newsgurufocus.com·34d ago·Negative
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit PR Newswire NEW YORK, S
View source ↗ - Newsglobenewswire.com·34d ago·Neutral
ARS Pharmaceuticals to Participate in Upcoming Investor Conferences SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to treat and prevent severe allergic reactions, today announced that Donn Casale, President and CEO, will participate in the following September investor conferences.
View source ↗ - Newsseekingalpha.com·49d ago·Neutral
ARS Pharma: New CEO's Program Of Reducing Costs While Increasing Revenues Makes A Buy ARS Pharmaceuticals has experienced a >65% decline since my previous 'Hold' rating, reflecting significant commercialization challenges. SPRY's Q2/2026 report highlights the new CEO's plans to reinvigorate its FDA-approved no-needle epinephrine product, neffy. The company's high-risk profile remains evident, but the high-reward potential is now the more compelling of the two.
View source ↗ - Newsgurufocus.com·50d ago·Negative
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit PR Newswire NEW YORK, A
View source ↗ - Newsseekingalpha.com·53d ago·Positive
ARS Pharmaceuticals, Inc. (SPRY) Q2 2026 Earnings Call Transcript ARS Pharmaceuticals, Inc. (SPRY) Q2 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·53d ago·Positive
ARS Pharmaceuticals Q2 Earnings Call Highlights ARS Pharmaceuticals NASDAQ: SPRY outlined a revised commercial and spending strategy during its second-quarter 2026 earnings call, with new President and CEO Donn Casale emphasizing provider-focused promotion for its neffy intranasal epinephrine product, lower operating expenses and an expected path to cash-flow breakeven by the end of 2027.
View source ↗ - Newszacks.com·53d ago·Negative
ARS Pharmaceuticals, Inc. (SPRY) Reports Q2 Loss, Tops Revenue Estimates ARS Pharmaceuticals, Inc. (SPRY) came out with a quarterly loss of $0.63 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to a loss of $0.46 per share a year ago.
View source ↗ - Newsnewsfilecorp.com·54d ago·Positive
Grabar Law Office Investigates Claims on Behalf of Long-Term Shareholders of ARS Pharmaceuticals, Inc. (SPRY) Philadelphia, Pennsylvania--(Newsfile Corp. - August 13, 2026) - Grabar Law Office is investigating claims on behalf of shareholders of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY). What is The Investigation About?
View source ↗ - Newsbusinesswire.com·57d ago·Neutral
ARS Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – SPRY LOS ANGELES--(BUSINESS WIRE)---- $SPRY--ARS Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – SPRY.
View source ↗ - Newsgurufocus.com·57d ago·Neutral
ARS Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SPRY ARS Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SPRY PR Newswir
View source ↗ - Newsbusinesswire.com·58d ago·Negative
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law LOS ANGELES--(BUSINESS WIRE)---- $SPRY--SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law.
View source ↗
Earnings
Mon, Nov 9(in 5 weeks)
Consensus estimate $-0.33 per share
Typical surprise -12.2% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 13$-0.63 vs $-0.48miss
- Fri, May 15$-0.61 vs $-0.53miss
- Mon, Mar 9$-0.42 vs $-0.42beat
- Mon, Nov 10$-0.52 vs $-0.45miss
- Wed, Aug 13$-0.46 vs $-0.41miss
- Wed, May 14$-0.35 vs $-0.35beat
Estimates and results for SPRY via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by SPRY officers and directors.
- Bought
- —
- Sold
- $18.4m
0 trades
23 trades
- Karas Ericsold
- Fitzpatrick Alexander Asold
- Dorsey Briansold
- Chakma Justinsold
- Chakma Justinsold
- Lowenthal Richard Esold
- Scott Kathleen D.sold
- Tanimoto Sarinasold
77 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in SPRY.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.